John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses the results from the interim analysis of the MPD-RC 112 study, which compared frontline pegylated interferon-alpha-2a (Pegasys) with hydroxyurea in the treatment of patients with high-risk polycythemia vera (PV) and essential thrombocythemia (ET).
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More